Skip to main content

Original Research

Business, Original Research

Comparing Treatment Persistence, Healthcare Resource Utilization, and Costs in Adult Patients with Major Depressive Disorder Treated with Escitalopram or Citalopram

Eric Q. Wu, PhD, Paul E. Greenberg, MA, Rym Ben-Hamadi, MSc, Andrew P. Yu, PhD, Elaine H. Yang, PhD, M. Haim Erder, PhD

Stakeholder Perspective

Efficacy and Cost-Effectiveness: Escitalopram versus Citalopram

by Matthew Mitchell, PharmD, MBA, FAMCP

Original Research

Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service

Helen Blumen, MD, MBA, Kathryn Fitch, RN, MEd, Vincent Polkus, MSEM, MBA

Stakeholder Perspective

An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer

by Michael Kleinrock

Business, Original Research

Computed Tomography Colonography Less Costly Than Colonoscopy for Colorectal Cancer Screening of Commercially Insured Patients

Tia Goss Sawhney, DrPH, FSA, MAAA, Bruce S. Pyenson, FSA, MAAA, David Rotter, PhD, Michele Berrios, Judy Yee, MD

Tia Goss Sawhney, DrPH, FSA, MAAA; Bruce S. Pyenson, FSA, MAAA; David Rotter, PhD; Michele Berrios; Judy Yee, MD

Clinical, Original Research

Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns

Fahamina Ahmed, PharmD, Shelby Gross, PharmD, Samah Hammad, PharmD Candidate, Candice Wilson, MPH, Batool Zeini, PharmD, George Nawas, PharmD, BCPS

Fahamina Ahmed, PharmD; Shelby Gross, PharmD; Samah Hammad, PharmD Candidate; Candice Wilson, MPH; George Nawas, PharmD, BCPS; Batool Zeini, PharmD

Business, Original Research

Cost-Effectiveness of de novo Simvastatin as Adjunctive Therapy in Patients Critically Ill with Sepsis

Sara Mosta Eladawy, MSc, PhD, Mohamed Abd Alsalam Elgendy, MD, Mamdouh Ahmed Zaki, MD, Naglaa Samir Bazan, MSc, PhD

Sara Mostafa Eladawy, MSc, PhD; Mohamed Abd Alsalam Elgendy, MD; Mamdouh Ahmed Zaki, MD; Naglaa Samir Bazan, MSc, PhD

Business, Original Research

Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models

Thomas Lodise, PhD, PharmD, Kenneth LaPensee, PhD, MPH

Thomas Lodise, PhD, PharmD; Kenneth LaPensee, PhD, MPH

Original Research

Cost-Savings Using Patients’ Own Medication Supply of Letermovir for Allogeneic Hematopoietic Stem-Cell Transplant Recipients During Hospitalization

Harrison S. Yoon, PharmD; Mallory Crain, PharmD, BCOP; Marissa Olson, PharmD, BCOP; Anupam Pande, MD, MPH; Jeff O. Klaus, PharmD, BCPS

Business, Original Research

Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer

Katherine M. Prioli, BS; Laura T. Pizzi, PharmD, MPH; Kathryn M. Kash, PhD; Andrew B. Newberg, MD; Anna Marie Morlino, PharmD; Michael J. Matthews, BS; Daniel A. Monti, MD

Stakeholder Perspective

Creative Therapeutic Activities and Support Groups Benefit All Those Involved in Cancer Care

Linda Bily, MA, CSA, OPN-CG

Business, Original Research

Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer

Krishna Tangirala, MPH; Sreevalsa Appukkuttan, MPH, MBBS; Stacey Simmons, MD

Clinical, Original Research

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry

Dimitrios A. Pappas, MD; Robert A. Gerber, PharmD; Heather J. Litman, PhD; David Gruben, PhD; Jamie Geier, PhD; Winnie D. Hua, MS; Connie Chen, PharmD; Youfu Li, MD, MPH; Joel M. Kremer, MD; John S. Andrews, MD; Jeffrey A. Bourret, PharmD

Stakeholder Perspective

Limited Guidelines and Treatment Success in the Current Standard of Care for Patients with Rheumatoid Arthritis Provide an Opportunity to Inform New Treatment Protocols

Gary Branning, MBA

1
2
3
4
5
6
7

Page 4 of 11
Results 31 - 40 of 110